Tompkins Financial Corp boosted its position in AbbVie Inc (NYSE:ABBV) by 201.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,383 shares of the company’s stock after purchasing an additional 20,986 shares during the period. Tompkins Financial Corp’s holdings in AbbVie were worth $2,789,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Formidable Asset Management LLC lifted its position in shares of AbbVie by 0.3% during the 2nd quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock valued at $285,000 after acquiring an additional 10 shares during the period. WealthTrust Axiom LLC lifted its position in shares of AbbVie by 0.3% during the 2nd quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock valued at $312,000 after acquiring an additional 15 shares during the period. Abner Herrman & Brock LLC lifted its position in shares of AbbVie by 0.3% during the 2nd quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock valued at $456,000 after acquiring an additional 18 shares during the period. St. Louis Trust Co lifted its position in shares of AbbVie by 0.7% during the 2nd quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock valued at $248,000 after acquiring an additional 23 shares during the period. Finally, TRUE Private Wealth Advisors lifted its position in shares of AbbVie by 0.6% during the 2nd quarter. TRUE Private Wealth Advisors now owns 4,814 shares of the company’s stock valued at $349,000 after acquiring an additional 27 shares during the period. Hedge funds and other institutional investors own 69.18% of the company’s stock.
In other AbbVie news, insider Henry O. Gosebruch sold 18,300 shares of AbbVie stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $90.55, for a total value of $1,657,065.00. Following the completion of the sale, the insider now directly owns 81,287 shares of the company’s stock, valued at approximately $7,360,537.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Timothy J. Richmond sold 87,040 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the sale, the senior vice president now directly owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The disclosure for this sale can be found here. Insiders sold a total of 494,676 shares of company stock valued at $47,237,938 over the last ninety days. 0.23% of the stock is owned by corporate insiders.
A number of equities research analysts have recently issued reports on ABBV shares. Zacks Investment Research upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $102.00 price target for the company in a research report on Tuesday, October 17th. BidaskClub downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 25th. Deutsche Bank lifted their price objective on AbbVie to $88.00 and gave the stock a “hold” rating in a research report on Thursday, September 28th. Jefferies Group restated a “buy” rating and set a $107.00 price objective (up from $94.00) on shares of AbbVie in a research report on Friday, September 15th. Finally, Vetr upgraded AbbVie from a “buy” rating to a “strong-buy” rating and set a $113.08 price objective for the company in a research report on Wednesday, December 20th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $100.94.
AbbVie Inc (NYSE ABBV) traded up $1.07 during mid-day trading on Friday, reaching $100.34. 4,372,638 shares of the company’s stock traded hands, compared to its average volume of 4,460,000. The stock has a market cap of $159,950.00, a PE ratio of 24.35, a P/E/G ratio of 1.20 and a beta of 1.53. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. AbbVie Inc has a 12-month low of $59.27 and a 12-month high of $101.28.
AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.02. The firm had revenue of $7 billion during the quarter, compared to analysts’ expectations of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. AbbVie’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.21 EPS. equities analysts anticipate that AbbVie Inc will post 5.55 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a $0.71 dividend. This is a boost from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 annualized dividend and a yield of 2.83%. The ex-dividend date is Thursday, January 11th. AbbVie’s payout ratio is presently 62.14%.
COPYRIGHT VIOLATION NOTICE: “Tompkins Financial Corp Increases Stake in AbbVie Inc (ABBV)” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://ledgergazette.com/2018/01/13/tompkins-financial-corp-raises-position-in-abbvie-inc-abbv.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.